Observed changes in the lipid profile and calculated coronary risk in patients given dietary advice in primary care.

BACKGROUND: Dietary advice is usually the first-line treatment for increased blood cholesterol in primary care with a reduction in levels as the expected response. In practice, the diet adopted by the patient may lead to changes in blood lipids characterised by a greater decrease in high-density lipoprotein (HDL) than total cholesterol. The ratio of total cholesterol to HDL cholesterol is an important factor in calculated coronary risk using the Framingham model, from which most risk tables currently in use have been derived. This suggests that either coronary risk may increase after dietary advice or that risk should always be assessed on measurements made before any intervention has taken place. AIM: To report observed changes in blood lipids and calculated coronary risk following dietary advice in primary care. METHOD: Subjects with at least one coronary risk factor and baseline cholesterol above 5.2 mmol/l from an inner-city general practice had cardiovascular risk factors, including fasting lipids, recorded before receiving dietary advice. At follow-up several months later, risk factor measurements were repeated. Ten-year coronary risk was calculated using the Framingham model. Lipid levels and coronary risk at baseline and follow-up were compared. RESULTS: There was a significant decrease in both total cholesterol and HDL cholesterol in both sexes. However, in 56% of subjects, HDL decreased by a greater proportion than the total cholesterol. These subjects showed a highly significant increase in the total cholesterol/HDL cholesterol ratio (median = 0.8 [semi-interquartile range = 1.5], P < 0.001, which was correlated with a change in triglycerides (rs = 0.309, P < 0.001). In those who had an increase in the total cholesterol/HDL cholesterol ratio, calculated coronary risk increased from 5.45% (13.2) at baseline to 7.25% (15.5) (P < 0.001). In all subjects, the change in calculated coronary risk associated with dietary advice ranged from -15% to 15%. CONCLUSIONS: Low fat dietary advice in this primary care setting was frequently associated with undesirable changes in the lipid profile. The majority of subjects showed an increase in the total cholesterol/HDL cholesterol ratio, owing primarily to a decrease in HDL. Consequently, calculated coronary risk increased in over one-half of the subjects. Owing to our incomplete understanding of HDL metabolism, it is unclear whether the fall in HDL is actually detrimental; however, it seems prudent to give dietary advice to patients to avoid excess simple carbohydrate as a fat substitute. This helps avoid a rise in triglycerides, which appears to be associated with an increase in the ratio. These results confirm that coronary risk should always be calculated using measurements made before intervention.

Fetal and maternal lipoprotein metabolism in human pregnancy complicated by type I diabetes mellitus.

Serum lipid, apolipoprotein concentration, and lipoprotein composition were determined in maternal and umbilical venous cord blood at delivery by elective Cesarean section (CS) in 10 singleton, full-term pregnancies with maternal insulin-dependent diabetes mellitus (type I DM), which predated pregnancy, and in 22 nondiabetic pregnancies. The objectives of the study were to determine the influence of maternal type I DM, and hence potential fetal overnutrition on fetal lipid metabolism. There were no significant differences in gestational age, fetal weight, or fetal serum insulin concentration between the type I DM group and those with nondiabetic pregnancies, although fetal venous cord blood glucose was 3.4 mmol/L (3.0-4.5 mmol/L) (median and 25th-75th percentiles) and 2.9 mmol/L (2.0-3.4 mmol/L), respectively, and maternal Hemoglobin A1c [9.6% (8.2-10.7%) and 6.8% (6.3-7.8%), respectively], was significantly greater in the type I DM subjects (P < 0.02 and 0.002 respectively). Plasma nonesterified fatty acid (NEFA) concentrations were lower in the type I DM mothers [0.85 mmol/L (0.56-2.31 mmol/L) compared with 1.14 mmol/L (0.88-1.24 mmol/L] in nondiabetic pregnancies; P < 0.0001). Serum high-density lipoprotein phospholipids (HDL-PL) were increased in type I DM mothers because of elevated HDL2 phospholipid [0.39 mmol/L (0.27-0.48 mmol/L) compared with 0.12 mmol/L (0.06-0.21 mmol/L), respectively, P < 0.01). The maternal HDL cholesterol (C) concentration was not significantly different in the uncomplicated and type I DM pregnancies. However, in the umbilical venous cord blood, serum levels of NEFA [0.49 mmol/L (0.33-1.29 mmol/L) in type I DM compared with 0.13 mmol/L (0.06-0.33 mmol/L) in nondiabetics; P < 0.02)], total cholesterol (TC) [2.87 mmol/L (1.65-4.86 mmol/L) in type I DM compared with 1.65 mmol/L (1.46-1.87 mmol/L) in nondiabetics; P < 0.02]; free cholesterol (FC) [0.97 mmol/L (0.60-1.26 mmol/L) in type I DM compared with 0.62 mmol/L (0.37-0.75 mmol/L) in nondiabetics; P < 0.05), and cholesteryl ester (CE) [1.90 mmol/L (1.44-3.33 mmol/L) in type I DM compared with 1.01 mmol/L (0.83-1.24 mmol/L) in nondiabetics; P < 0.02), triglyceride (TG) (1.06 [0.50-1.91) mmol/L in type I DM compared with 0.29 [0.25-0.36] mmol/l in nondiabetics; P < 0.001), phospholipid (PL) (2.52 [1.73-3.03) mmol/L in type I DM compared with 1.34 [1.27-1.48] mmol/L in nondiabetics; P < 0.01], and the apolipoproteins A-I and B had significantly higher concentrations in type I DM. In umbilical venous cord blood, ratios of HDL-TC and HDL-PL to apo AI, reflecting the lipid content of HDL, were reduced when the mother had type I DM during pregnancy (P < 0.02 and P < 0.0001, respectively). These results indicate that maternal type I DM may lead to a fetal serum lipoprotein composition more closely resembling that seen in the adult. In type I DM, maternal TG and PL and fetal TC, TG, PL, CE, and FC were correlated to NEFA levels (P < 0.05), but not to glucose, insulin secretion, or maternal control of type I DM. These data suggest that the enhanced supply of NEFA to the fetus in type I DM pregnancies may drive the synthesis of cholesterol as well as TGs and PLs.

Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.

Women with polycystic ovary syndrome (PCOS) appear at increased cardiovascular risk due in part to a dyslipidemia characterized by increased plasma triglyceride and reduced high density lipoprotein (HDL) cholesterol levels. This is a detailed exploratory study of HDL composition in 35 obese [body mass index (BMI), > 27] and 22 nonobese subjects with PCOS and in 14 healthy obese and 18 nonobese women. Although we found reduced levels of total and HDL2 cholesterol in obese women with PCOS, HDL composition was modified by depletion of lipid relative to protein, with reduced ratios of HDL total cholesterol and HDL phospholipids to apolipoprotein A-I (apoA-I) compared to those in obese controls (P = 0.008 and P = 0.012, respectively). This was explained by reduced cholesterol (P = 0.004) and phospholipid (although not significant, P = 0.07) in HDL with no change in the content of apoA-I, its major protein. Obesity, insulin resistance, and hyperandrogenemia are features of PCOS and potentially affect lipid metabolism. Insulin sensitivity was assessed by the reduction in endogenous glucose concentration after exogenous insulin; the insulin, glucose, and fatty acid responses to oral glucose; and the fasting insulin concentration. When age, BMI, free androgen index, insulin sensitivity determined by all methods, and the presence of PCOS were subjected to stepwise multivariate regression analysis, the presence of PCOS was the most consistent predictor of lipid-depleted HDL (HDL total cholesterol/apoA-I and HDL phospholipids/apoA-I). We speculate that altered activity of hepatic lipase or lipid transfer protein could explain this aspect of the dyslipidemia. Obesity has an important influence on the lipid profile. Obese PCOS and control subjects had higher levels of cholesterol, triglyceride, apoB, and fatty acids than their lean counterparts, and BMI proved the best predictor of blood levels on multiple regression analysis. In contrast, lean PCOS patients had normal sensitivity to insulin and lipid profiles similar to those of the lean controls and did not manifest the HDL abnormalities. Although in PCOS, correlations were obtained between the free androgen index and cholesterol, triglyceride, and apoB levels and between the integrated glucose and insulin responses after oral glucose and fasting fatty acid and triglyceride levels, when age and adiposity were included as covariates only fatty acids and the integrated glucose response remained significantly correlated. Among the controls, total, low density lipoprotein cholesterol, triglycerides, and apoB were related to aspects of insulin sensitivity independent of age and BMI. Lipid metabolism in PCOS is dependent on several related factors, but subjects with PCOS who are obese show a specific reduction in HDL lipid, suggesting a reduced capacity for cholesterol removal from tissues with diminished antiatherogenic potential. Efforts should be directed toward reducing obesity in PCOS to improve the metabolic disturbance in addition to ameliorating the presenting symptoms.

Risk factors for ischaemic heart disease in patients with dermatitis herpetiformis.

For reasons that are unclear, patients with dermatitis herpetiformis (DH) have a lower than expected mortality rate from ischaemic heart disease. We have compared risk factors for ischaemic heart disease (lipids, fibrinogen levels, smoking history and social class) in 29 DH patients and 57 controls matched for age and sex. Patients with DH had significantly lower cholesterol, triglycerides, apolipoprotein B and fibrinogen and higher HDL2; they also smoked less and were of higher social class. The mechanisms underlying these observations merit further investigation. Intestinal abnormalities or gluten-free diet may account for differences in lipid fractions, and the immunomodulatory properties of cigarette smoke may protect against the development of DH.

Does an increase in the sensitivity of serum thyrotropin assays reduce diagnostic costs for thyroid disease in the community?

Many authorities now advocate that the first-line assessment of thyroid function should be measurement of thyrotropin (TSH). The latest serum TSH assays (third generation) are more sensitive than the second generation but the reagents are more costly. We have examined whether overall assay reagent costs would be higher or lower with a third-generation assay, in a laboratory that serves a population of almost 500,000. In a prospective study over six weeks, 505 samples with a second-generation serum TSH less than 0.5 mU/L (303 for screening and 202 for monitoring thyroxine therapy) had an additional third-generation TSH analysis. With a second-generation assay for screening, 11% more free thyroxine (FT4) measurements were required to exclude thyrotoxicosis but there was a 42% saving on the reagent budget compared with a third-generation assay. In patients taking thyroxine, 33% more FT4 measurements were required to exclude over-replacement but the calculated saving in reagent costs was 53%. The costs of all other aspects of the two methods were similar. In this community-based sample, the improvement in sensitivity yielded by the third-generation assay at the lower end of the normal range reduced the number of confirmatory FT4 levels required to exclude thyrotoxicosis or over-replacement with thyroxine, but reagent costs were nevertheless higher than for second-generation assays. In financial terms, there is little justification for use of assays with sensitivity greater than the second generation (0.1 mU/L).

Fetal and maternal lipoprotein metabolism in human pregnancy.

1. Lipid, apolipoprotein concentration and composition were determined in maternal venous and umbilical arterial and venous blood at delivery by elective Caesarean section in 13 full-term pregnancies and in 25 healthy non-pregnant females. The indications of Caesarean section were a previous Caesarean section or breech presentation. None of the women was in labour and there were no other complications of pregnancy or fetal distress. 2. The objectives of the study were to establish whether the placenta has a role in feto-maternal cholesterol metabolism through either synthesis or transplacental cholesterol flux. The potential for free cholesterol diffusion between mother and fetus and rates of cholesterol esterification and transfer between lipoproteins were determined and related to the differences in composition between fetal and maternal lipoproteins. 3. Pregnant women had raised levels of all lipid and lipoprotein fractions compared with control subjects. The greatest increases were in free cholesterol and triacylglycerol (P < 0.0001). Lipoprotein (a) levels were significantly greater in the pregnant women [112 (12.2) mg/l] than in the control women [50 (10.0) mg/l]. 4. The only significant correlation between maternal and fetal lipoprotein concentrations was in lipoprotein (a) levels (r = 0.791, P = 0.002). In both umbilical venous and arterial blood, concentrations of very-low- and low-density lipoproteins, particularly apolipoprotein B, cholesteryl ester and triacylglycerol, were lower than in maternal blood (P < 0.0001), but high-density lipoprotein levels were similar. 5. There was no umbilical arteriovenous differences in lipoprotein concentration or composition. This suggests that cholesterol synthesis or free cholesterol diffusion does not occur in the placenta.(ABSTRACT TRUNCATED AT 250 WORDS)

Normolipaemic plane xanthomas: an association with increased vascular permeability and serum lipoprotein(a) concentration.

We present a normolipaemic young man with extensive facial plane xanthomas and xanthelasmas with a high level of lipoprotein(a) and possibly increased vascular permeability. These associations are of potential importance in understanding the pathogenesis of xanthoma formation and in the identification of patients at risk from coronary atherosclerosis.

The effect of renal failure and haemodialysis on the concentration of free apolipoprotein A-1 in serum and the implications for the catabolism of high-density lipoproteins.

Free apolipoprotein A-1 (free A-1) was measured by quantitative crossed immunoelectrophoresis in 43 patients with severe chronic renal failure. The free A-1 concentrations in these patients were higher than in 28 healthy subjects irrespective of whether they where receiving haemodialysis or conservative treatment. A close correlation was found between serum concentration of free A-1 and creatinine in patients with varying degrees of chronic renal failure (r = 0.717, p less than 0.001). In three patients who received renal transplants serial measurements of free A-1 showed a decrease to normal levels within two days post-operatively. These findings suggest a relationship between the serum concentration of free A-1 and glomerular filtration. In conjunction with the report implicating the kidney as the major site of catabolism of Apo A-1 in the rat, these results suggest a similar role for the kidney in man. No evidence has been found linking free A-1 with hypertriglyceridaemia in patients with renal failure as has been suggested previously.

Stability of free apolipoprotein A-1 concentration in serum, and its measurement in normal and hyperlipidemic subjects.

Free apolipoprotein A-1 (free A-1) is a low-molecular-mass complex of protein and lipid containing apolipoprotein A-1 (apo A-1). Using crossed immunoelectrophoresis, we separated free A-1 from the apo A-1 in high-density lipoproteins (HDL) and quantified free A-1 by comparison with a reference serum (containing 1.45 g of apo A-1 per liter) diluted in 9 mol/L urea solution. This latter treatment yields apo A-1 containing protein-lipid complexes of the same size and electrophoretic mobility as free A-1. Within-day precision (CV), determined by replicate analysis of two samples with mean free A-1 concentrations of 48 and 138 mg/L, was 9.1 and 7.2%, respectively. We also showed that the concentration of free A-1 is not stable in serum or plasma either at 4 degrees C or when frozen. The mean concentration of free A-1 in 28 fasted, healthy subjects was 75.3 (SD 13.6) mg/L. The postprandial increase was not statistically significant. The percentage of total apo A-1 in the free form in serum ranged from 3.5% to 8.1%, less than the 10% to 30% reported by others who used radial immunodiffusion to measure free A-1. Because radial immunodiffusion does not separate free A-1 from HDL, we believe that that technique overestimates free A-1. We also used crossed immunoelectrophoresis to measure free A-1 in 76 hyperlipidemic patients. Those with Fredrickson types III and V had significantly increased concentrations of free A-1 (P less than .0001). Correlations between free A-1 and cholesterol and triglycerides in serum were significant (P less than .005 and P less than .001, respectively). Possible roles for free A-1 in lipid metabolism are discussed.